Abstract
Chronic hepatitis C (HCV) infection is a systemic life-threatening condition that can lead to hepatic and extra-hepatic complications. Sustained virological response (SVR) is associated with a regression of most liver and non-liver manifestations, which reduce mortality. The history of HCV infection therapy radically changed in the last decade, with the introduction of the first generation direct acting antivirals (DAAs). Areas covered: The new regimens, based on the combination of 2 or 3 second-generation DAAs, allow SVR, namely hepatitis C infection cure, in more than 95% of cases. Antiviral treatment is generally well tolerated and its duration (8-16 weeks) varies depending on the stage of liver fibrosis, HCV genotype, prior treatment, baseline viral load, presence of resistance-associated variants (RAV). This review evaluates the cause, the efficacy and safety results in case of DAAs failure. Expert commentary: Despite the excellent efficacy of DAAs, a minority of patients (4-5%) still fail to eradicate HCV, mainly related to poor adherence but also to relapse or viral breakthrough. The main causes of a failure of DAAs are the presence of advanced liver disease, suboptimal treatment and NS5A mutations. Many questions regard...Continue Reading
References
Jan 28, 2004·Human Pathology·Stanislas PolChristian Bréchot
Apr 28, 2012·Gastroenterology·Stéphane ChevaliezJean-Michel Pawlotsky
May 6, 2014·The New England Journal of Medicine·T Jake Liang, Marc G Ghany
Apr 26, 2015·Journal of Hepatology·UNKNOWN European Association for Study of Liver
Jun 23, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Erik LontokVeronica Miller
Sep 28, 2015·Journal of Hepatology·Christoph Sarrazin
Feb 9, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Christophe HézodeJean-Michel Pawlotsky
Apr 16, 2016·Gastroenterology·Jean-Michel Pawlotsky
Jun 25, 2016·Antiviral Therapy·Ana AriasCarmen de Mendoza
Sep 13, 2016·The Lancet Infectious Diseases·Kali ZhouJoseph D Tucker
Sep 20, 2016·Gastroenterology·Pierre NahonUNKNOWN ANRS CO12 CirVir Group
Sep 26, 2016·The Lancet Infectious Diseases·Louisa DegenhardtTheo Vos
Jan 22, 2017·Journal of Hepatology·Stefan ZeuzemMark Sulkowski
Jan 28, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Fred PoordadFederico J Mensa
Feb 22, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Eric LawitzJulio Gutierrez
Apr 12, 2017·The Lancet. Gastroenterology & Hepatology·UNKNOWN European Union HCV Collaborators
May 13, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Edward J GaneUNKNOWN GS-US-342-1553 Investigators
Jun 1, 2017·The New England Journal of Medicine·Marc BourlièreUNKNOWN POLARIS-1 and POLARIS-4 Investigators
Nov 21, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Fred PoordadFederico J Mensa
Dec 2, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Patrick R HarringtonLisa K Naeger
Apr 21, 2018·Liver International : Official Journal of the International Association for the Study of the Liver· Manoj KumarShiv K Sarin
Jul 1, 2018·Gastroenterology·Rafael EstebanMaria Buti
Sep 15, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·UNKNOWN AASLD-IDSA HCV Guidance Panel
Citations
May 6, 2020·PloS One·Felix PiechaJulian Schulze Zur Wiesch
May 5, 2020·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Saima AslamUNKNOWN working group members
Jul 31, 2021·World Journal of Gastroenterology : WJG·María B PisanoPamela Valva
May 21, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Caroline E BoekeChristian B Ramers
Jun 22, 2021·Antimicrobial Agents and Chemotherapy·Yanira Sáez-ÁlvarezMiguel A Martín-Acebes